華恆生物(688639.SH):赤峯智合擬實施生物法年產5萬噸1,3-丙二醇建設項目
格隆匯12月7日丨華恆生物(688639.SH)公佈,為充分發揮公司已構建的合成生物平台研發和生物製造能力,不斷豐富公司產品類型,持續增強企業盈利能力,經公司第四屆董事會二次會議審議通過,同意由公司控股子公司天津智合生物科技有限公司(簡稱“天津智合”)的全資子公司赤峯智合實施生物法年產5萬噸1,3-丙二醇建設項目。投資金額不超過人民幣4億元。預計建設期為24個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.